This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Social Bookmarking   What's this?

Arch Ophthalmol. 2002;120:633.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

IN 1968, the trabeculectomy procedure was introduced as a surgical treatment for glaucoma.¹ Although this procedure was a major improvement to what was then available in the glaucoma surgical armamentarium, it has its limitations because of the need to enter the eye.

The past several decades have witnessed major advances in cataract surgery and vitreoretinal surgery. In stark contrast, there have been relatively minor advances in glaucoma surgery, and trabeculectomy remains the procedure of choice for most eyes with glaucoma requiring surgical treatment. One advance has been the adjunctive use of antifibrotic agents, such as fluorouracil and mitomycin, with trabeculectomy. These agents have improved the success rate of trabeculectomy, particularly in eyes at high risk for filtration failure. However, the need to enter the eye persists as does the potential complications, some of which are devastating.

Nonpenetrating filtration surgeries—viscocanalostomy and deep sclerectomy—have recently been advocated by some as preferable to . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Enzymatic Sclerostomy: Pilot Human Study
Jacob A. Dan, Santosh G. Honavar, David A. Belyea, Anil K. Mandal, Chandrasekhar Garudadri, Brian Levy, Rengappa Ramakrishnan, Ramasamy Krishnadas, Marc F. Lieberman, Robert L. Stamper, and Arieh Yaron
Arch Ophthalmol. 2002;120(5):548-553.
ABSTRACT | FULL TEXT